Drug Profile


Alternative Names: A-422894.0; ABT-894

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abbott Laboratories; NeuroSearch
  • Developer Abbott Laboratories
  • Class Analgesics
  • Mechanism of Action Alpha4beta2 nicotinic receptor modulators; Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder; Cognition disorders
  • Discontinued Diabetic neuropathies

Most Recent Events

  • 23 Jan 2013 No development reported - Phase-II for Attention-deficit hyperactivity disorder in USA (PO)
  • 23 Jan 2013 No development reported - Preclinical for Cognition disorders in USA (PO)
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top